Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China

Aims To estimate the long‐term cost‐effectiveness of exenatide twice daily vs insulin glargine once daily as add‐on therapy to oral antidiabetic agents ( OADs ) for Chinese patients with type 2 diabetes ( T2DM ). Methods The Cardiff Diabetes Model was used to simulate disease progression and estimate the long‐term effects of exenatide twice daily vs insulin glargine once daily. Patient profiles and treatment effects required for the model were obtained from literature reviews (English and Chinese databases) and from a meta‐analysis of 8 randomized controlled trials comparing exenatide twice daily with insulin glargine once daily add‐on to OADs for T2DM in China. Medical expenditure data were collected from 639 patients with T2DM (aged ≥18 years) with and without complications incurred between January 1, 2014 and December 31, 2015 from claims databases in Shandong, China. Costs (2014 Chinese Yuan [¥]) and benefits were estimated, from the payers’ perspective, over 40 years at a discount rate of 3%. A series of sensitivity analyses were performed. Results Patients on exenatide twice daily + OAD had a lower predicted incidence of most cardiovascular and hypoglycaemic events and lower total costs compared with those on insulin glargine once daily + OAD . A greater number of quality‐adjusted life years (QALYs; 1.94) at a cost saving of ¥117 706 gained was associated with exenatide twice daily vs insulin glargine once daily. (i.e. cost saving of ¥60 764/ QALY ) per patient. Conclusions In Chinese patients with T2DM inadequately controlled by OADs , exenatide twice daily is a cost‐effective add‐on therapy alternative to insulin glargine once daily, and may address the problem of an excess of medical needs resulting from weight gain and hypoglycaemia in T2DM treatment.